Scolaris Content Display Scolaris Content Display

Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia

Abstract

available in

Background

Choroidal neovascularisation (CNV) is a common complication of pathological myopia. Once developed, most eyes with myopic CNV (mCNV) experience a progression to macular atrophy, which leads to irreversible vision loss. Anti‐vascular endothelial growth factor (anti‐VEGF) therapy is used to treat diseases characterised by neovascularisation and is increasingly used to treat mCNV.

Objectives

To assess the effects of anti‐vascular endothelial growth factor (anti‐VEGF) therapy for choroidal neovascularisation (CNV), compared with other treatments, sham treatment or no treatment, in people with pathological myopia.

Search methods

We searched a number of electronic databases including CENTRAL and Ovid MEDLINE, ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform ICTRP). We did not use any date or language restrictions in the electronic searches for trials. Electronic databases were last searched on 16 June 2016.

Selection criteria

We included randomised controlled trials (RCTs) and quasi‐RCTs comparing anti‐VEGF therapy with another treatment (e.g. photodynamic therapy (PDT) with verteporfin, laser photocoagulation, macular surgery, another anti‐VEGF), sham treatment or no treatment in participants with mCNV.

Data collection and analysis

We used standard methodological procedures expected by Cochrane. Two authors independently screened records, extracted data, and assessed risk of bias. We contacted trial authors for additional data. We analysed outcomes as risk ratios (RRs) or mean differences (MDs). We graded the certainty of the evidence using GRADE.

Main results

The present review included six studies which provided data on the comparison between anti‐VEGF with PDT, laser, sham treatment and another anti‐VEGF treatment, with 594 participants with mCNV. Three trials compared bevacizumab or ranibizumab with PDT, one trial compared bevacizumab with laser, one trial compared aflibercept with sham treatment, and two trials compared bevacizumab with ranibizumab. Pharmaceutical companies conducted two trials. The trials were conducted at multiple clinical centres across three continents (Europe, Asia and North America). In all these six trials, one eye for each participant was included in the study.

When compared with PDT, people treated with anti‐VEGF agents (ranibizumab (one RCT), bevacizumab (two RCTs)), were more likely to regain vision. At one year of follow‐up, the mean visual acuity (VA) in participants treated with anti‐VEGFs was ‐0.14 logMAR better, equivalent of seven Early Treatment Diabetic Retinopathy Study (ETDRS) letters, compared with people treated with PDT (95% confidence interval (CI) ‐0.20 to ‐0.08, 3 RCTs, 263 people, low‐certainty evidence). The RR for proportion of participants gaining 3+ lines of VA was 1.86 (95% CI 1.27 to 2.73, 2 RCTs, 226 people, moderate‐certainty evidence). At two years, the mean VA in people treated with anti‐VEGFs was ‐0.26 logMAR better, equivalent of 13 ETDRS letters, compared with people treated with PDT (95% CI ‐0.38 to ‐0.14, 2 RCTs, 92 people, low‐certainty evidence). The RR for proportion of people gaining 3+ lines of VA at two years was 3.43 (95% CI 1.37 to 8.56, 2 RCTs, 92 people, low‐certainty evidence). People treated with anti‐VEGFs showed no obvious reduction (improvement) in central retinal thickness at one year compared with people treated with PDT (MD ‐17.84 μm, 95% CI ‐41.98 to 6.30, 2 RCTs, 226 people, moderate‐certainty evidence). There was low‐certainty evidence that people treated with anti‐VEGF were more likely to have CNV angiographic closure at 1 year (RR 1.24, 95% CI 0.99 to 1.54, 2 RCTs, 208 people). One study allowed ranibizumab treatment as of month 3 in participants randomised to PDT, which may have led to an underestimate of the benefits of anti‐VEGF treatment.

When compared with laser photocoagulation, there was more improvement in VA among bevacizumab‐treated people than among laser‐treated people after one year (MD ‐0.22 logMAR, equivalent of 11 ETDRS letters, 95% CI ‐0.43 to ‐0.01, 1 RCT, 36 people, low‐certainty evidence) and after two years (MD ‐0.29 logMAR, equivalent of 14 ETDRS letters, 95% CI ‐0.50 to ‐0.08, 1 RCT, 36 people, low‐certainty evidence).

When compared with sham treatment, people treated with aflibercept had better vision at one year (MD ‐0.19 logMAR, equivalent of 9 ETDRS letters, 95% CI ‐0.27 to ‐0.12, 1 RCT, 121 people, moderate‐certainty evidence). The fact that this study allowed for aflibercept treatment at 6 months in the control group might cause an underestimation of the benefit with anti‐VEGF.

People treated with ranibizumab had similar improvement in VA recovery compared with people treated with bevacizumab after one year (MD ‐0.02 logMAR, equivalent of 1 ETDRS letter, 95% CI ‐0.11 to 0.06, 2 RCTs, 80 people, moderate‐certainty evidence).

Of the included six studies, two studies reported no adverse events in either group and two industry‐sponsored studies reported both systemic and ocular adverse events. In the control group, there were no systemic or ocular adverse events reported in 149 participants. Fifteen people reported systemic serious adverse events among 359 people treated with anti‐VEGF agents (15/359, 4.2%). Five people reported ocular adverse events among 359 people treated with anti‐VEGF agents (5/359, 1.4%). The number of adverse events was low, and the estimate of RR was uncertain regarding systemic serious adverse events (4 RCTs, 15 events in 508 people, RR 4.50, 95% CI 0.60 to 33.99, very low‐certainty evidence) and serious ocular adverse events (4 RCTs, 5 events in 508 people, RR 1.82, 95% CI 0.23 to 14.71, very low‐certainty evidence). There were no reports of mortality or cases of endophthalmitis or retinal detachment.

There was sparse reporting of data for vision‐related quality of life (in favour of anti‐VEGF) in only one trial at one year of follow‐up. The studies did not report data for other outcomes, such as percentage of participants with newly developed chorioretinal atrophy.

Authors' conclusions

There is low to moderate‐certainty evidence from RCTs for the efficacy of anti‐VEGF agents to treat mCNV at one year and two years. Moderate‐certainty evidence suggests ranibizumab and bevacizumab are equivalent in terms of efficacy. Adverse effects occurred rarely and the trials included here were underpowered to assess these. Future research should be focused on the efficacy and safety of different drugs and treatment regimens, the efficacy on different location of mCNV, as well as the effects on practice in the real world.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

Anti‐VEGF for treatment of choroidal neovascularisation (new blood vessels) in people with pathological (severe) myopia

What is the aim of this review?
The aim of this Cochrane Review was to find out if anti‐vascular endothelial growth factor (called anti‐VEGF) treatment of new blood vessels in people with severe myopia (also known as nearsightedness or shortsightedness) prevents vision loss. Cochrane researchers collected and analysed all relevant studies to answer this question and found six studies.

Key messages
People with severe myopia and growth of new blood vessels at the back of the eye may benefit from treatment with anti‐VEGF. It may prevent vision loss. SIde effects (harms) occur rarely.

What was studied in the review?
Myopia occurs when the eyeball becomes too long. If the myopia is severe, sometimes the retina (light‐sensitive tissue at the back of the eye) becomes too thin and new blood vessels grow. These new blood vessels can leak and cause vision loss.

Anti‐vascular endothelial growth factor (anti‐VEGF) is a drug that may slow down the growth of these new vessels. Doctors can inject anti‐VEGF into the eye of people who have severe myopia and signs of new blood vessels growing at the back of the eye. This may prevent vision loss.

What are the main results of the review?
The Cochrane researchers found six relevant studies. These studies took place in multiple clinical centres across three continents (Europe, Asia and North America), Three studies compared anti‐VEGF treatment with photodynamic therapy (PDT; a treatment with a light‐sensitive medicine and a light source that destroys abnormal cells); one study compared anti‐VEGF with laser treatment; one study compared anti‐VEGF with no treatment; and two studies compared different types of anti‐VEGF to each other. In some of the studies, the comparison group received anti‐VEGF after a short period which may mean that the results underestimate the beneficial effect of anti‐VEGF.

The results of the review show that:

• People with severe myopia who have anti‐VEGF treatment probably achieve better vision than people receiving PDT, laser or no treatment (moderate‐ and low‐certainty evidence).
• Two different types of anti‐VEGF ‐ ranibizumab and bevacizumab ‐ probably have similar effects on vision (moderate‐certainty evidence).
• Side effects (harms) occur rarely.

How up‐to‐date is this review?
The Cochrane researchers searched for studies that had been published up to 16 June 2016.